It’s not every day that a weight loss shot gets upgraded to “heart protector” status. But that’s exactly what
happened when the U.S. Food and Drug Administration (FDA) approved Wegovy (semaglutide) not just for weight loss,
but also to help prevent major cardiovascular events like heart attacks and strokes in certain adults.

If you’ve heard people call Wegovy a “game changer,” this newest FDA decision is a big part of why. It’s the first
time a prescription weight loss medication has been officially approved to reduce the risk of serious heart
problems in adults with obesity or overweight who also have established cardiovascular disease. That puts Wegovy
in a new category: not just a cosmetic weight loss aid, but a tool for protecting long-term heart health when used
correctly, under medical supervision.

What Exactly Did the FDA Approve?

The new cardiovascular indication in plain English

Originally, Wegovy was approved as a once-weekly injection to help adults with obesity (or overweight with at
least one weight-related condition) lose weight alongside diet and exercise. In March 2024, the FDA expanded that
label. Wegovy is now approved to reduce the risk of major cardiovascular eventsspecifically cardiovascular death,
heart attack, and strokein adults who:

• Have established cardiovascular disease (like prior heart attack, stroke, or peripheral artery disease), and
• Have obesity or are overweight.

In other words, this isn’t about helping someone drop 10 pounds for a beach vacation. It’s a targeted therapy for
adults whose weight and heart health are deeply linked and who are already at high risk for serious events.

The starring ingredient: semaglutide 2.4 mg

Wegovy’s active ingredient, semaglutide, is a GLP-1 receptor agonist. That’s a fancy way of saying it mimics a
natural gut hormone that:

• Helps regulate appetite and fullness
• Supports blood sugar control
• Improves certain cardiometabolic risk factors, like blood pressure and cholesterol levels, in many patients

At the 2.4 mg weekly dose used in Wegovy, semaglutide goes beyond modest weight changes. Studies show meaningful
weight loss and, critically, a reduction in the risk of major heart-related events in high-risk patients.

How Does Wegovy Help Protect the Heart?

The SELECT trial: the big study behind the decision

The FDA’s cardiovascular approval for Wegovy is based largely on the SELECT trial, a large, international,
randomized clinical study. This trial followed people who:

• Had overweight or obesity
• Had established cardiovascular disease
• Did not have diabetes

Participants received either semaglutide 2.4 mg once weekly or a placebo, on top of their usual heart medications
and lifestyle recommendations. Over several years, the semaglutide group had significantly fewer major cardiovascular
eventsthings like cardiovascular death, non-fatal heart attacks, and non-fatal strokescompared with the placebo
group.

Put simply: adding Wegovy to standard care lowered the risk of the kinds of events that shorten lives and change
them forever.

It’s not “just” the weight loss

Yes, Wegovy helps people lose a meaningful amount of weight. But that’s only part of the story. GLP-1 medicines
like semaglutide appear to support the heart in multiple ways, including:

• Reducing inflammation and oxidative stress in blood vessels
• Lowering blood pressure in many patients
• Improving cholesterol and triglyceride profiles
• Supporting healthier blood sugar control and insulin sensitivity

The combination of significant weight loss plus direct cardiovascular benefits likely explains why the SELECT trial
showed fewer heart attacks and strokes in the semaglutide group. This is one reason professional societies,
including cardiology organizations, are increasingly talking about GLP-1 drugs as tools for cardiovascular risk
reductionnot just weight loss.

Who Is Wegovy For Now?

With its updated approval, Wegovy is aimed at a very specific group of adults. In general, it may be considered if
someone:

• Has a body mass index (BMI) in the overweight or obesity range, and
• Has existing cardiovascular disease (such as prior heart attack, stroke, or narrowed arteries), and
• Is already working on lifestyle measures like diet, physical activity, and not smoking.

A key nuance: Wegovy’s heart-protective indication is not about “preventing heart disease from ever starting” in
completely healthy people. It’s about reducing future major cardiovascular events in people already living with
heart disease plus excess weight.

Wegovy is prescription-only and is not appropriate for everyone. It’s also not recommended for people with a
history of certain thyroid cancers or a rare endocrine condition called MEN2, among other exclusions. That’s why
the decision to start Wegovy should always be made with a healthcare professional who knows your full medical
history.

How Wegovy Is Taken

Wegovy is a once-weekly injection given under the skin (usually in the abdomen, thigh, or upper arm). Most people
use a pre-filled pen at home after being trained by their healthcare provider. To reduce side effects, the dose is
gradually increased over several weeks until it reaches the maintenance dose, usually 2.4 mg once weekly.

Wegovy is meant to be used along with:

• A reduced-calorie, nutritious eating pattern
• Regular physical activity, tailored to the person’s condition
• Other heart medications like blood pressure pills, statins, or antiplatelet drugs, as prescribed

Benefits Beyond the Scale

Weight loss plus risk reduction

For eligible patients, Wegovy offers a powerful two-for-one benefit:

1. Significant weight loss. Many people lose a meaningful percentage of their starting weight over time.
2. Fewer major heart events. In high-risk adults, adding Wegovy to standard care significantly reduces the
   risk of heart attack, stroke, and cardiovascular death.

Beyond those headline benefits, patients and clinicians often see improvements in:

• Blood pressure
• Cholesterol and triglycerides
• Markers of inflammation
• Mobility, exercise tolerance, and daily energy levels

Of course, not everyone experiences the same results, and no medication guarantees protection. But for the right
person, Wegovy shifts the odds in a more favorable direction.

Risks and Side Effects: What to Know

The common, annoying stuff

If Wegovy had a tagline, it might be “Effective, but your stomach may complain at first.” The most common side
effects of semaglutide are gastrointestinal and tend to show up early, especially when doses are being increased.
These can include:

• Nausea
• Vomiting
• Diarrhea or constipation
• Abdominal pain or bloating
• Heartburn or indigestion
• Feeling unusually full after small meals

Many people find these side effects improve over time, especially if they:

• Eat smaller, slower meals
• Avoid greasy, heavy foods
• Stay hydrated
• Follow the dose escalation schedule carefully

More serious warnings

Wegovy also carries important safety warnings. These include:

• Risk of thyroid C-cell tumors in animal studies. Wegovy is not recommended for people with certain
  types of thyroid cancer or MEN2.
• Pancreatitis (inflammation of the pancreas). Severe abdominal pain that won’t go away is a red flag.
• Gallbladder problems such as gallstones, sometimes related to rapid weight loss.
• Low blood sugar when used with other diabetes medicines that can cause hypoglycemia.
• Kidney problems, sometimes linked to dehydration from severe vomiting or diarrhea.
• Mood changes: any thoughts of self-harm or major mood shifts deserve immediate attention.

None of this means Wegovy is “too dangerous” to use. It means it’s a powerful prescription medication that needs
to be used thoughtfully, with real follow-upnot something to grab off a social media ad and start on your own.

Always talk to your healthcare provider about whether Wegovy is right for your specific situation, and never stop
or change heart or diabetes medications without medical guidance.

How Wegovy Compares to Other Weight Loss Drugs

Wegovy isn’t the only modern weight loss injection in town, but it has a unique calling card: as of the FDA’s 2024
decision, it’s the first weight loss medication with a specific approval for reducing major cardiovascular events
in people with obesity or overweight and established heart disease.

Other drugs in this category, including medications that target both GLP-1 and GIP hormones, may lead to even
greater weight loss in some studies. However, Wegovy currently has some of the strongest and clearest evidence
connecting its use to fewer heart attacks, strokes, and cardiovascular deaths in the high-risk group studied.

Over time, more medications may earn similar cardiovascular indications. For now, Wegovy holds a special place as a
bridge between obesity treatment and heart protection.

Is Wegovy a Good Option for You?

If you:

• Have had a heart attack, stroke, or other major cardiovascular issue, and
• Are also living with overweight or obesity, and
• Have struggled to lose enough weight through lifestyle measures alone

…Wegovy may be worth discussing with your cardiologist, primary care doctor, or endocrinologist.

A good clinician will look at:

• Your full heart history and other conditions (like kidney disease or diabetes)
• Medications you already take
• Your personal preferences, comfort with injections, and ability to attend follow-ups
• Insurance coverage, out-of-pocket costs, and whether you can realistically stay on therapy

Wegovy is not a magic wand. But for the right person, it can be a powerful part of a comprehensive plan that also
includes nutrition, movement, sleep, stress management, and other evidence-based treatments.

Practical Tips If You’re Starting Wegovy

• Go slow on dose increases. Rushing through the dose escalation is a classic way to feel miserable.
• Prioritize protein and resistance training. You want to lose fat, not muscle.
• Keep a symptom diary. Track nausea, appetite changes, and energy levels to share with your clinician.
• Don’t skip heart meds. Wegovy is an add-on, not a replacement for blood pressure pills, statins, or
  other proven therapies.
• Plan for follow-up. Expect regular check-ins to monitor blood pressure, lab work, and side effects.

Experiences and Stories Around Wegovy and Heart Health

While every person’s situation is unique, the way Wegovy’s new approval plays out in real life often follows some
common themes. Imagine a few composite storiesfictional, but built from what patients and clinicians frequently
report.

Take “Mark,” a 59-year-old who had a heart attack three years ago. He’s on a statin, blood pressure medications,
aspirin, and has tried repeatedly to lose weight. He knows he “should” exercise more and change his eating
patterns, but every attempt turns into a short-term burst followed by discouragement. When his cardiologist
explains that Wegovy isn’t just about the number on the scale but also about reducing his future risk of heart
attack and stroke, Mark is suddenly more engaged. The idea that losing weight could tie directly into fewer
life-threatening events gives the plan more urgencyand more meaning.

The first month is rocky. Mark feels queasy, especially if he eats too quickly. With coaching, he switches to
smaller, protein-focused meals, eats more slowly, and avoids “greasy drive-thru experiments” after injections.
Gradually, the nausea eases. Over several months, he loses a substantial amount of weight. His blood pressure
improves, and his LDL cholesterol drops. He still has to manage stress, take his medications, and show up for
follow-up appointments, but for the first time in years, he feels like his effort is actually paying off.

Then there’s “Angela,” 66, who has had a stroke and struggles with mobility. Losing weight isn’t about aesthetics
for herit’s about staying independent and avoiding another catastrophic event. Wegovy, combined with
physical therapy and simple at-home resistance exercises, helps her shed enough weight to move more comfortably.
She notices less breathlessness on short walks and is able to participate more in daily activities. Her care team
focuses on small, realistic wins: getting her blood pressure to goal, improving sleep, and making sure her diet
supports both cardiovascular health and muscle maintenance.

Clinicians’ experiences add another layer. Many cardiologists describe Wegovy as a valuable new tool in a toolbox
that already includes lifestyle counseling, statins, blood pressure drugs, and antiplatelet medications. They
appreciate that the SELECT trial and FDA indication are very specificthis is for patients with established
cardiovascular disease and excess weight, not for “everyone who wants to slim down.” The best results tend to
happen when the medication is integrated into a broader, long-term relationship with patients instead of treated
like a quick fix.

On the flip side, there are real frustrations. Some patients can’t tolerate the gastrointestinal side effects,
even with slow dose titration. Others face insurance barriers or supply shortages, making it hard to stay on
consistent therapy. A few are disappointed that even with Wegovy, they don’t get the dramatic social-media-style
transformation they were hoping for. Those experiences are just as important to acknowledge, because they remind
us that medications, no matter how promising, are never one-size-fits-all.

Taken together, these experiences highlight what the FDA’s new approval really means. Wegovy is not a miracle and
not a substitute for the basicsbut it can tilt the odds. For people already living with heart disease and the
burden of excess weight, that tilt toward fewer heart attacks and strokes can be life-changing. The key is using
Wegovy thoughtfully, with a realistic plan, good follow-up, and a clear understanding that the medication works
best as part of a bigger picture of heart-healthy living.

Bottom Line

With its expanded FDA approval, Wegovy is officially more than a weight loss drug. For adults with obesity or
overweight and established cardiovascular disease, it is now a proven option to help reduce the risk of major
events like heart attacks and strokes when used alongside lifestyle changes and standard heart therapies.

It’s powerful, it’s promising, and it’s not for everyone. If you think Wegovy might be right for youor for
someone you care aboutthe next step isn’t a hashtag or a quick online order. It’s a real conversation with a
healthcare professional who can look at the whole picture: your heart, your weight, your goals, and your life.

The post Weight Loss Drug Wegovy Approved by FDA to Prevent Heart Attacks and Strokes appeared first on Global Travel Notes.